Nyra Medical's Strategic Leadership Expansion to Propel CARLEN Clinical Evaluation Forward

Nyra Medical Expands Leadership to Enhance CARLEN's Development

Nyra Medical, Inc., a pioneering company in the medical technology arena, has recently taken significant steps to strengthen its leadership team. This move comes as the firm aims to advance its investigational CARLEN™ System, a cutting-edge solution for addressing functional mitral regurgitation (FMR). The appointments of Suzanne Wallace and Scott Tyler are pivotal in reinforcing Nyra's clinical and market development strategies at this critical stage of growth.

New Appointments Boost Leadership Team

On October 27, 2026, Nyra Medical announced the onboarding of Suzanne Wallace, CRNP, as the Vice President of Clinical and Market Development, and Scott Tyler as the Senior Director of Clinical Engineering and Development. These strategic appointments are expected to provide a complementary blend of expertise, encompassing clinical strategy, commercialization, and structural heart engineering, which are paramount as the company progresses through its U.S. Early Feasibility Study (EFS).

Wallace brings over 15 years of experience in the medtech domain, having previously held key positions at notable firms such as Vesper Medical, Shockwave Medical, and HeartWare. Her extensive background in clinical marketing, medical affairs, and commercialization equips her with the necessary insights to guide Nyra in building stronger partnerships with physicians, articulating the unique value propositions of CARLEN, and translating recent clinical data into actionable strategies for market adoption.

Tyler, with more than 12 years dedicated to structural heart technologies, has significant experience in transcatheter therapies. His prior roles at Edwards Lifesciences, including leadership positions in engineering and therapy, make him well-suited to lead clinical engineering and procedural development at Nyra. He will focus on translating clinical insights into product improvements and best practices, significantly enhancing the company's developmental trajectory.

Advancing CARLEN's Clinical Evaluation

The CARLEN System is designed to provide a novel transcatheter approach that aims to improve outcomes in patients suffering from FMR. This investigational device seeks to restore mitral leaflet coaptation while preserving the valve’s natural motion—addressing the limitations of current treatment options. As Nyra embarks on this next phase of clinical evaluations, it aims to build a robust clinical evidence base and procedural experience that could pave the way for wider adoption of the CARLEN System across various healthcare settings.

Lori Chmura, CEO of Nyra Medical, expressed her confidence in these new leadership roles, stating, "These appointments come at an important point in Nyra's development. Our first-in-human experience has provided a strong foundation as we refine CARLEN and advance our Early Feasibility Study." Chmura further emphasized that the combination of Wallace's and Tyler's expertise will enhance the synergy between clinical execution and physician engagement, ultimately aiming to deliver significant improvements to patient care in the realm of mitral valve disorders.

Looking Ahead

As Nyra Medical progresses with its clinical evaluation of the CARLEN System, the company is committed to expanding its research across additional studies and geographical regions. By focusing on solidifying clinical evidence and procedural consistency, Nyra anticipates a breakthrough in the management of functional mitral regurgitation.

Nyra Medical’s endeavors not only reflect a commitment to innovation in medical technology but also underscore the importance of assembling a skilled leadership team capable of navigating the complexities of clinical trials and establishing new treatment paradigms in cardiology.

In conclusion, Nyra Medical stands on the brink of significant advancements in the field of cardiac care. With new leadership at the helm and a dedicated approach to refining their investigational CARLEN System, they are well-positioned to shape the future of treatments for mitral valve conditions and improve patient outcomes globally.